SLC5A2 and type 2 diabetes mellitus: For example, cost-utility analyses project a favorable ICER (Incremental Cost-Effectiveness Ratio) for semaglutide in T2D and show that SGLT2 inhibitors deliver QALY (Quality-Adjusted Life Year) gains with event-related cost offsets; value improves further as drug prices decline [71,72,73].